CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 224 enrolled
Drug / intervention
Teriparatide +4 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00887354
NCT00887354Phase 4Completed
CompareCT.gov

Comparison of the Effects of Teriparatide With Those of Risedronate on Lumbar Spine BMD (Bone Mineral Density) in Men and Postmenopausal Women With Low Bone Mass and a Recent Pertrochanteric Hip Fracture

Eli Lilly and Company·interventional·Posted Apr 24, 2009·Updated Sep 25, 2019

In Brief

A Phase 4 clinical trial evaluating Teriparatide, Risedronate, and 3 other interventions for Osteoporosis. Completed, enrolled 224 participants across 28 sites in 12 countries.

Detailed Summary

This study will evaluate whether teriparatide is superior to the active comparator in the change from baseline of lumbar spine BMD (bone mineral density) in men and postmenopausal women with low bone mass and a recent pertrochanteric hip fracture.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsOsteoporosis
CountriesCanada, Croatia, Czechia, Denmark, France, Germany, Greece, Italy, Mexico, Norway, Spain, United States
Collaborators--

Timeline

Phase 4CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedApr 24, 2009
Enrollment StartApr 1, 2009
Primary CompletionAug 1, 2015
TodayJul 2, 2026
Enrollment to primary: 6.3 yearsPosted 17.2 years ago

Interventions

Teriparatidedrug

Administered subcutaneously

Risedronatedrug

Administered orally

Placebodrug

Weekly: Administered orally Daily: Administered subcutaneously

Calciumdietary

Approximately 500 to 1000 mg/day administered orally throughout study.

Vitamin Ddietary

Approximately 800 International Units per day (IU/day) administered orally throughout study.